The state-owned enterprise responsible for the manufacture of pharmaceuticals in Thailand says it plans to produce a licenced version of Favipiravir, the anti-viral drug that has proved successful in treating some Covid-19 patients.
Nation Thailand reports that The Government Pharmaceutical Organisation developed the drug in March, but there is a waiting period of about a year before the product can complete the registration process. The GPO must also secure an agreement with the owner of the Favipiravir patent and be granted a licence to produce and distribute its version, without the risk of being sued for patent infringement.
In 2010, FujiFilm Toyama Chemical, the Japanese manufacturers of Favipiravir, reportedly lodged an application to produce the drug in Thailand, which never went any further. Meanwhile, the Zhejiang Hisun Pharmaceutical Company in China was granted a production licence and, along with the Japanese, have been shipping the drug to Thailand during the current pandemic.
To date, Thailand has imported 187,000 Favipiravir tablets and is due to purchase more than 300,000 this month. The tablets are being sent to hospitals all over the country.
SOURCE: Nation Thailand
Join the conversation and have your say on Thailand news published on The Thaiger.
Thaiger Talk is our new Thaiger Community where you can join the discussion on everything happening in Thailand right now.
Please note that articles are not posted to the forum instantly and can take up to 20 min before being visible. Click for more information and the Thaiger Talk Guidelines.